Which patients would you treat with relugolix instead of injectable GnRH agonist therapy?

I would consider relugolix for patients with:

1. Intermediate-risk prostate cancer that needs a short course of androgen deprivation therapy

2. Patients with biochemical relapse that would benefit from a short course of ADT and salvage RT

2.5 Patient with pre-existing cardiac comorbidities

3. Potentially patients with biochemical relapse

My rationale for relugolix in the above patients is due to rapid testosterone recovery and cardiac benefits noted in the HERO study.

It is yet to be determined if...